<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01789112</url>
  </required_header>
  <id_info>
    <org_study_id>12-032</org_study_id>
    <nct_id>NCT01789112</nct_id>
  </id_info>
  <brief_title>Acute Effects of a Non Excitatory Cardial Stimulation</brief_title>
  <official_title>Acute Neurotrophic Effects of a Non Excitatory Cardial Stimulation by Optimizer III System in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <brief_summary>
    <textblock>
      Electric stimulation by cardial contractility modulation (CCM)to improve contractility and
      physical capacity
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>positive inotropic effects by CCM stimulation</measure>
    <time_frame>15 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>CCM Implantation</condition>
  <arm_group>
    <arm_group_label>CCM aggregate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taking of 10 blood samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Taking of blood sample</description>
    <arm_group_label>CCM aggregate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  planned CCM Implantation

          -  systolic left ventricular dysfunction despite of adequate therapy of heart failure
             (NYHA II, III, IV)

          -  implanted pacemaker, defibrillator or pacemaker during CS intubation

          -  written informed consent

          -  open entryways

        Exclusion Criteria:

          -  anemia Hemoglobin (HB)&lt;8 mg/dl

          -  lying coronary sinus (CS) tube or CS being not able to intubate

          -  chronic atrial fibrillation or flutter

          -  mechanic tricuspid valve prothesis

          -  no access via subclavian vein

          -  patients with VVI pacemaker being stimulated 110%

          -  idiopathic hypertrophic cardiomyopathy, restrictive constrictive cardiomyopathy or
             heart failure because of known inflammatory or infiltrative illnesses or constrictive
             illness

          -  acute myocardial ischemia presented by angina pectoris or ECG changes under load

          -  patients being hospitalized because of heart failure during the last month and have to
             be treated with intravenous diuretics or inotropic substances

          -  acute coronary syndrome should not be implanted for at least 3 month

          -  patients with mechanic aortic or tricuspid valve

          -  patients after heart transplantation

          -  patients with clinical significant ectopy, defined by &gt; 8.900 PVCs during 24 hours at
             beginning Holter monitoring

          -  patients after hypertensive crisis

          -  patients with acute renal failure

          -  Ejection Fraction (EF) &gt; 35

          -  patients after left ventricular pacemaker electrode

          -  pregnant or breast feeding women

          -  patients with heart failure after sepsis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Reith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH Aachen, Medical Departement I Univerity Hospital Aachen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <state>North Rhine Westfalia</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

